(Finance) – The European Commission has approvedunder the EU Merger Regulation, the acquisition the joint control of Baxter Pharmaceutical Solutions in the United States and Baxter Oncology in Germany by the US private equity firms Advent and Warburg Pincus.
BPS extension partners with pharmaceutical companies to support their commercialization goals by providing scientific expertise, manufacturing solutions, delivery systems, and customized support services.
The Commission concluded that the proposed acquisition it would not raise competition problemsgiven the limited combined market position of the companies and the limited vertical relationships resulting from the proposed transaction. The transaction was examined under the simplified procedure.